Related Experiment Video

Updated: Nov 16, 2025

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
12:03

Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method

Published on: April 18, 2019

26.9K

Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections

Young-A Heo1

  • 1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.

Drugs
|February 25, 2021
PubMed

Insights

Imipenem/cilastatin/relebactam (Recarbrio™) offers effective treatment for serious gram-negative bacterial infections, including hospital-acquired pneumonia. This combination therapy shows efficacy against resistant strains and is well-tolerated in adult patients.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Antimicrobial Resistance

Background:

  • Imipenem/cilastatin/relebactam (Recarbrio™) is an intravenous combination therapy.
  • Relebactam inhibits class A and C β-lactamases, restoring imipenem activity against resistant bacteria.
  • Approved for hospital-acquired bacterial pneumonia (HABP), ventilator-associated bacterial pneumonia (VABP), and other serious gram-negative infections.

Purpose of the Study:

  • To evaluate the efficacy and safety of imipenem/cilastatin/relebactam.
  • To assess its role in treating infections caused by imipenem-nonsusceptible pathogens.
  • To position it as a treatment option for patients with limited alternatives.

Main Methods:

  • Pivotal Phase II and III clinical trials were conducted.
  • Comparisons were made against piperacillin/tazobactam for HABP/VABP.
  • Comparisons were made against imipenem/cilastatin for complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections (cIAIs).

Main Results:

  • Noninferiority demonstrated against piperacillin/tazobactam in HABP/VABP.
  • Noninferiority demonstrated against imipenem/cilastatin in cUTIs and cIAIs.
  • Effective treatment was observed in imipenem-nonsusceptible infections.

Conclusions:

  • Imipenem/cilastatin/relebactam is an effective and well-tolerated treatment for gram-negative infections in adults.
  • It provides a valuable option for critically ill patients and those with carbapenem-resistant pathogens.
  • The safety profile is consistent with imipenem/cilastatin.

More Related Videos

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.1K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.2K

Related Concept Videos

Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
126
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
5.8K
Urinary Tract Infection I: Introduction01:26

Urinary Tract Infection I: Introduction

Urinary tract infections (UTIs) impact various parts of the urinary system, including the kidneys, ureters, bladder, and urethra. These infections are generally bacterial, with Escherichia coli being the most common causative agent, often originating from the gastrointestinal tract. However, other bacteria, such as Staphylococcus saprophyticus, Klebsiella pneumoniae, and Proteus mirabilis, are also known to cause UTIs. The type, location, and underlying complexity of the UTI guide both...
267
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
115
Urine Studies II: Urine Culture and Sensitivity Test01:26

Urine Studies II: Urine Culture and Sensitivity Test

A urine culture and sensitivity test is a diagnostic procedure used to identify urinary tract bacterial infections and determine the most effective antibiotics for treatment. This test is generally preferred when a patient shows manifestations of a urinary tract infection, such as frequent or painful urination, cloudy or foul-smelling urine, or lower abdominal pain.Purpose of the TestThe primary goals of a urine culture and sensitivity test are to:Determine the specific bacteria causing the...
354
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
75